ArticleAnnals of neurology2022
Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy.
Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Independent effects of white matter lesion volume and APOE ɛ4 on ARIA-H in A4 Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2024Trial
- Plasma Amyloid Beta and Tau Associations with Cerebral Amyloid Angiopathy Presence and Severity.Annals of neurology · 2026Article
- Independent and interactive contributions of white matter hyperintensities and Alzheimer's disease imaging and plasma biomarkers to cognitive decline in older adults without dementia.Alzheimer's research & therapy · 2026Article
- Review
- Pathological mechanisms of motor dysfunction in familial Danish dementia: insights from a knock-in rat model.Journal of neuroinflammation · 2025Article
- One-Year Radiologic Progression in Sporadic and Hereditary Cerebral Amyloid Angiopathy.Neurology · 2025Article
- Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know.Japanese journal of radiology · 2025Review
- Neuropathological contributions to grey matter atrophy and white matter hyperintensities in amnestic dementia.Alzheimer's research & therapy · 2025Article
- Neuropathological Correlates of White Matter Hyperintensities in Cerebral Amyloid Angiopathy.Journal of the American Heart Association · 2024Article
- Microstructural white matter damage on MRI is associated with disease severity in Dutch-type cerebral amyloid angiopathy.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Microstructural white matter integrity in relation to vascular reactivity in Dutch-type hereditary cerebral amyloid angiopathy.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- The Boston criteria version 2.0 increase the proportion of lobar intracerebral haemorrhage classified as probable cerebral amyloid angiopathy.Journal of neurology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 4 countries.
Funding
Abstract
Autosomal-dominant, Dutch-type cerebral amyloid angiopathy (D-CAA) offers a unique opportunity to develop biomarkers for pre-symptomatic cerebral amyloid angiopathy (CAA). We hypothesized that neuroimaging measures of white matter injury would be present and progressive in D-CAA prior to hemorrhagic lesions or symptomatic hemorrhage. In a longitudinal cohort of D-CAA carriers and non-carriers, we observed divergence of white matter injury measures between D-CAA carriers and non-carriers prior to the appearance of cerebral microbleeds and >14 years before the average age of first symptomatic hemorrhage. These results indicate that white matter disruption measures may be valuable cross-sectional and longitudinal biomarkers of D-CAA progression. ANN NEUROL 2022;92:358-363.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.